DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://link.springer.com/article/10.1007/s11596-021-2469-0, but it redirected us to https://link.springer.com/article/10.1007/s11596-021-2469-0. The analysis below is for the second page.

Title[redir]:
Curcumin Synergizes with Cisplatin to Inhibit Colon Cancer through Targeting the MicroRNA-137-Glutaminase Axis | Current Medical Science
Description:
Objective Colorectal cancer (CRC) is one of the most lethal and prevalent malignancies world-wide. Currently, surgery, radiotherapy and chemotherapy are clinically applied as common approaches for CRC patients. Cisplatin is one of the most frequently used chemotherapy drugs for diverse cancers. Although chemotherapeutic strategies have improved the prognosis and survival of cancer patients, development of cisplatin resistance has led to cancer recurrence. Curcumin, isolated from turmeric, has been used as an effective anti-cancer agent. However, the molecular mechanisms for curcumin-mediated cisplatin sensitivity of CRC have not been elucidated. This study aimed to investigate the effects of curcumin treatment on cisplatin-resistant CRC cells. Methods Expression levels of miRNAs and mRNAs were determined by qRT-PCR. Protein expression levels were detected by Western blotting. Cell responses to curcumin treatments were evaluated by MTT assay, Clonogenic assay and Annexin V apoptosis assay. The glutamine metabolism of colon cancer cells was assessed by glutamine uptake and glutaminase (GLS) activity. The binding of miR-137 on 3′ UTR of GLS was validated by Western blotting and luciferase assay. Results Results demonstrated that curcumin significantly synergized with cisplatin (combination index <1) to suppress proliferation of colon cancer cells compared with curcumin or cisplatin alone. Moreover, from the established cisplatin-resistant cell line (HT-29), glutamine metabolism was remarkedly elevated in cisplatin-resistant CRC cells that displayed a glutamine addictive phenotype. Furthermore, curcumin treatments attenuated glutamine metabolism in colon cancer cells. Under low glutamine supply, colon cancer cells showed less sensitivity to curcumin. Using a microRNA (miRNA) microArray assay, miR-137, a tumor suppressor in colon cancer, was significantly induced by curcumin treatments in CRC cells. Bioinformatics analysis and a luciferase assay illustrated miR-137 directly targeted the 3′ UTR of GLS mRNA. Rescue experiments demonstrated that miR-137-induced cisplatin sensitization was through targeting of GLS. Finally, curcumin treatment overcame cisplatin resistance through miR-137-mediated glutamine inhibition. Conclusion Collectively, these results indicate that curcumin could be clinically applied as an anti-chemoresistance approach against CRC by modulating miR-137-inhibited glutamine metabolism.

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We're unsure if the website is profiting.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Doi.org might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

article, cancer, curcumin, google, scholar, cas, glutamine, cisplatin, colon, cells, metabolism, crc, cell, targeting, wang, colorectal, assay, privacy, cookies, content, resistance, publish, search, zhang, mechanisms, gls, microrna, access, therapy, drug, data, information, log, journal, research, fan, jin, zhu, jianxin, chemotherapy, molecular, treatment, cisplatinresistant, expression, treatments, apoptosis, glutaminase, results, inhibits, discover,

Topics {✒️}

clinically-promising anti-cancer agent month download article/chapter inhibits epithelial-mesenchymal transition effective anti-cancer agent jian-xin zhang prevalent malignancies world-wide cisplatin-resistant crc cells microrna-137-glutaminase axis published mir-137-mediated glutamine inhibition mir-137-induced cisplatin sensitization colon cancer cells curcumin-mediated cisplatin sensitivity full article pdf microrna-137-glutaminase axis inhibit colon cancer privacy choices/manage cookies related subjects anti-chemoresistance approach glutamine addictive phenotype low glutamine supply circrna-microrna code microrna expression profile mir-137 regulates ferroptosis feng-chun wang curcumin synergizes cancer metabolism colorectal cancer article fan mir-137 suppresses proliferation european economic area protein expression levels rescue experiments demonstrated hif-1α induced cell cycle arrest arreguin camacho lo restrains stemness features cell death differ cancerous colonic tissue lymph node metastasis traditional chinese medicine curcumin significantly synergized conditions privacy policy glutamine metabolism curcumin induces apoptosis key factor colon cancer surg oncol clin accepting optional cookies curcumol blocks glutaminolysis cisplatin resistance

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Curcumin Synergizes with Cisplatin to Inhibit Colon Cancer through Targeting the MicroRNA-137-Glutaminase Axis
         description:Colorectal cancer (CRC) is one of the most lethal and prevalent malignancies world-wide. Currently, surgery, radiotherapy and chemotherapy are clinically applied as common approaches for CRC patients. Cisplatin is one of the most frequently used chemotherapy drugs for diverse cancers. Although chemotherapeutic strategies have improved the prognosis and survival of cancer patients, development of cisplatin resistance has led to cancer recurrence. Curcumin, isolated from turmeric, has been used as an effective anti-cancer agent. However, the molecular mechanisms for curcumin-mediated cisplatin sensitivity of CRC have not been elucidated. This study aimed to investigate the effects of curcumin treatment on cisplatin-resistant CRC cells. Expression levels of miRNAs and mRNAs were determined by qRT-PCR. Protein expression levels were detected by Western blotting. Cell responses to curcumin treatments were evaluated by MTT assay, Clonogenic assay and Annexin V apoptosis assay. The glutamine metabolism of colon cancer cells was assessed by glutamine uptake and glutaminase (GLS) activity. The binding of miR-137 on 3′ UTR of GLS was validated by Western blotting and luciferase assay. Results demonstrated that curcumin significantly synergized with cisplatin (combination index <1) to suppress proliferation of colon cancer cells compared with curcumin or cisplatin alone. Moreover, from the established cisplatin-resistant cell line (HT-29), glutamine metabolism was remarkedly elevated in cisplatin-resistant CRC cells that displayed a glutamine addictive phenotype. Furthermore, curcumin treatments attenuated glutamine metabolism in colon cancer cells. Under low glutamine supply, colon cancer cells showed less sensitivity to curcumin. Using a microRNA (miRNA) microArray assay, miR-137, a tumor suppressor in colon cancer, was significantly induced by curcumin treatments in CRC cells. Bioinformatics analysis and a luciferase assay illustrated miR-137 directly targeted the 3′ UTR of GLS mRNA. Rescue experiments demonstrated that miR-137-induced cisplatin sensitization was through targeting of GLS. Finally, curcumin treatment overcame cisplatin resistance through miR-137-mediated glutamine inhibition. Collectively, these results indicate that curcumin could be clinically applied as an anti-chemoresistance approach against CRC by modulating miR-137-inhibited glutamine metabolism.
         datePublished:2021-12-26T00:00:00Z
         dateModified:2021-12-26T00:00:00Z
         pageStart:108
         pageEnd:117
         sameAs:https://doi.org/10.1007/s11596-021-2469-0
         keywords:
            glutamine metabolism
            microRNA-137
            curcumin
            cisplatin resistant
            glutaminase
            Medicine/Public Health
            general
         image:
         isPartOf:
            name:Current Medical Science
            issn:
               2523-899X
               2096-5230
            volumeNumber:42
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Huazhong University of Science and Technology
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Wen-hui Fan
               affiliation:
                     name:the Second Hospital of Shandong University
                     address:
                        name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Feng-chun Wang
               affiliation:
                     name:the Second Hospital of Shandong University
                     address:
                        name:Department of Vascular Surgery, the Second Hospital of Shandong University, Jinan, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Zhi Jin
               affiliation:
                     name:the Second Hospital of Shandong University
                     address:
                        name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lin Zhu
               affiliation:
                     name:the Second Hospital of Shandong University
                     address:
                        name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jian-xin Zhang
               affiliation:
                     name:the Second Hospital of Shandong University
                     address:
                        name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Curcumin Synergizes with Cisplatin to Inhibit Colon Cancer through Targeting the MicroRNA-137-Glutaminase Axis
      description:Colorectal cancer (CRC) is one of the most lethal and prevalent malignancies world-wide. Currently, surgery, radiotherapy and chemotherapy are clinically applied as common approaches for CRC patients. Cisplatin is one of the most frequently used chemotherapy drugs for diverse cancers. Although chemotherapeutic strategies have improved the prognosis and survival of cancer patients, development of cisplatin resistance has led to cancer recurrence. Curcumin, isolated from turmeric, has been used as an effective anti-cancer agent. However, the molecular mechanisms for curcumin-mediated cisplatin sensitivity of CRC have not been elucidated. This study aimed to investigate the effects of curcumin treatment on cisplatin-resistant CRC cells. Expression levels of miRNAs and mRNAs were determined by qRT-PCR. Protein expression levels were detected by Western blotting. Cell responses to curcumin treatments were evaluated by MTT assay, Clonogenic assay and Annexin V apoptosis assay. The glutamine metabolism of colon cancer cells was assessed by glutamine uptake and glutaminase (GLS) activity. The binding of miR-137 on 3′ UTR of GLS was validated by Western blotting and luciferase assay. Results demonstrated that curcumin significantly synergized with cisplatin (combination index <1) to suppress proliferation of colon cancer cells compared with curcumin or cisplatin alone. Moreover, from the established cisplatin-resistant cell line (HT-29), glutamine metabolism was remarkedly elevated in cisplatin-resistant CRC cells that displayed a glutamine addictive phenotype. Furthermore, curcumin treatments attenuated glutamine metabolism in colon cancer cells. Under low glutamine supply, colon cancer cells showed less sensitivity to curcumin. Using a microRNA (miRNA) microArray assay, miR-137, a tumor suppressor in colon cancer, was significantly induced by curcumin treatments in CRC cells. Bioinformatics analysis and a luciferase assay illustrated miR-137 directly targeted the 3′ UTR of GLS mRNA. Rescue experiments demonstrated that miR-137-induced cisplatin sensitization was through targeting of GLS. Finally, curcumin treatment overcame cisplatin resistance through miR-137-mediated glutamine inhibition. Collectively, these results indicate that curcumin could be clinically applied as an anti-chemoresistance approach against CRC by modulating miR-137-inhibited glutamine metabolism.
      datePublished:2021-12-26T00:00:00Z
      dateModified:2021-12-26T00:00:00Z
      pageStart:108
      pageEnd:117
      sameAs:https://doi.org/10.1007/s11596-021-2469-0
      keywords:
         glutamine metabolism
         microRNA-137
         curcumin
         cisplatin resistant
         glutaminase
         Medicine/Public Health
         general
      image:
      isPartOf:
         name:Current Medical Science
         issn:
            2523-899X
            2096-5230
         volumeNumber:42
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Huazhong University of Science and Technology
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Wen-hui Fan
            affiliation:
                  name:the Second Hospital of Shandong University
                  address:
                     name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Feng-chun Wang
            affiliation:
                  name:the Second Hospital of Shandong University
                  address:
                     name:Department of Vascular Surgery, the Second Hospital of Shandong University, Jinan, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Zhi Jin
            affiliation:
                  name:the Second Hospital of Shandong University
                  address:
                     name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lin Zhu
            affiliation:
                  name:the Second Hospital of Shandong University
                  address:
                     name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jian-xin Zhang
            affiliation:
                  name:the Second Hospital of Shandong University
                  address:
                     name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Medical Science
      issn:
         2523-899X
         2096-5230
      volumeNumber:42
Organization:
      name:Huazhong University of Science and Technology
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:the Second Hospital of Shandong University
      address:
         name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
         type:PostalAddress
      name:the Second Hospital of Shandong University
      address:
         name:Department of Vascular Surgery, the Second Hospital of Shandong University, Jinan, China
         type:PostalAddress
      name:the Second Hospital of Shandong University
      address:
         name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
         type:PostalAddress
      name:the Second Hospital of Shandong University
      address:
         name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
         type:PostalAddress
      name:the Second Hospital of Shandong University
      address:
         name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Wen-hui Fan
      affiliation:
            name:the Second Hospital of Shandong University
            address:
               name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
               type:PostalAddress
            type:Organization
      name:Feng-chun Wang
      affiliation:
            name:the Second Hospital of Shandong University
            address:
               name:Department of Vascular Surgery, the Second Hospital of Shandong University, Jinan, China
               type:PostalAddress
            type:Organization
      name:Zhi Jin
      affiliation:
            name:the Second Hospital of Shandong University
            address:
               name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
               type:PostalAddress
            type:Organization
      name:Lin Zhu
      affiliation:
            name:the Second Hospital of Shandong University
            address:
               name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
               type:PostalAddress
            type:Organization
      name:Jian-xin Zhang
      affiliation:
            name:the Second Hospital of Shandong University
            address:
               name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
      name:Department of Vascular Surgery, the Second Hospital of Shandong University, Jinan, China
      name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
      name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
      name:Department of Traditional Chinese Medicine, the Second Hospital of Shandong University, Jinan, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(123)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

3.92s.